SMC Radiation Oncology Breast Cancer Cohort Study
Launched by SAMSUNG MEDICAL CENTER · Mar 7, 2023
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
The SMC Radiation Oncology Breast Cancer Cohort Study is looking to understand the side effects and cosmetic results of a specific type of radiation treatment called hypofractionated radiotherapy in women with breast cancer. The study aims to find out how this treatment affects the skin on the breast, what factors might influence these changes, and how patients feel about their treatment and recovery. Researchers will gather information through photographs, skin measurements, and questionnaires before and after the radiation therapy.
To participate in this study, women between the ages of 65 and 74 who have had surgery for breast cancer may be eligible, as long as they have not previously received radiation therapy to the chest area. If you join, you'll be assessed in various ways to track any changes in your skin and to gather your feedback on how you feel about the treatment. This study is currently recruiting participants, and your involvement could help improve understanding of radiation side effects in breast cancer care.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Breast cancer treated with curative surgery
- Exclusion Criteria:
- • History of thoracic radiation therapy
About Samsung Medical Center
Samsung Medical Center (SMC) is a leading healthcare institution in South Korea, renowned for its commitment to advancing medical research and innovation. As a prominent clinical trial sponsor, SMC integrates cutting-edge technology and expert clinical practices to conduct rigorous studies aimed at improving patient outcomes. The center is dedicated to fostering collaborations with global research entities and adhering to the highest ethical standards, ensuring the integrity and reliability of its clinical trials. With a focus on diverse therapeutic areas, SMC plays a pivotal role in translating scientific discoveries into effective treatments, ultimately enhancing the quality of healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Haeyoung Kim, MD, PhD
Principal Investigator
Samsung Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials